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INTRODUCTION
Hepatocellular carcinoma (HCC) is probably the commonest malignant tumour in
males in the world and is responsible for approximately 1,000,000 deaths
annually1’2. In China, most of Southeast Asia and Sub-Saharan Africa it occurs at a
rate of 20 to 150 per 100,000 a year, whilst in the USA and Europe the rate ranges
from 1 to 5 per 100,000 a year3’4. In all countries it shows a marked male
preponderance.
AETIOLOGY
Two major aetiological factors for HCC have been identified: Persistent Hepatitis
B Virus (HBV) infection and liver cirrhosis. Both of these show marked geographi-
cal variations.
Evidence for the role of the HBV comes mainly from epidemiological studies.
The worldwide prevalence of HBV infection is at least ten-times higher in
Southeast Asia and Africa than in North America and Western Europe and this
parallels the incidence of HCC. In addition there seems to be an increase in the
prevalence of HBV-markers in patients with HCC when compared to the local
population. A prospective study in Taiwan determined that the relative risk of
developing HCC was more than 200-fold greater in individuals who were HBsAg
(Hepatitis B surface antigen) carriers
6 and the risk is said to be greater when the
carrier state is acquired in early life5’6’7. The precise mechanism by which persistent
HBV infection and the development ofHCC are related remains largely unknown.
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Chronic carriage and cirrhosis seem to need to exist for 10-40 years before the
tumour develops and only a fraction of persistent HBV carriers will eventually
develop HCC8. It may be that HCC is initiated simply as a result of the increased
cell turnover that occurs in cirrhosis or it may be that the HBV has a special role in
initiating the tumour1’5’9. Integrated viral DNA has been demonstrated in both
normal liver from chronic HBV carriers and in tumour tissue from such patients
who have developed HCC1. More interestingly it has also been demonstrated in
tumour tissue from patients who were negative for all HBV markers
la suggesting
that the role of the HBV in causing this tumour may be even more extensive than
has been demonstrated by serological surveys. Whether other hepatitis viruses also
play a role in causing HCC is currently unknown although evidence is emerging to
suggest a role for Hepatitis C virus2.
The other major risk factor identified is liver cirrhosis. The tumour seems to
develop in cirrhotic livers about three times as often as in non-cirrhotic liversa3 and
cirrhosis co-exists with HCC in approximately 70% of cases in both high and low
risk countriesaa-a8. In high-risk countries, cirrhosis and HCC usually share the
common aetiology of HBV infection whilst in low-risk countries most cirrhosis is
alcoholic in origin. There is no evidence that alcohol has a direct carcinogenic
effect4’19 and indeed the risk of HCC is increased in all types of cirrhosis. It may
simply be that increased cell turnover increases the chance of malignancy or that
the presence of cirrhosis in some way increase an individuals’ susceptibility to
environmental carcinogens. It has been stated that the risk is greater in macronodu-
lar cirrhosis irrespective of its aetiology, and that alcoholic cirrhosis and haemoch-
romatosis carry particularly high risks19. However, if adjustment is made for
male:female differences the risks may in fact be similar for all types of cirrhosis2
including that secondary to chronic HBV infection.
Although over 90% of HCC can be correlated with HBV, or cirrhosis, or both,
other minor risk factors also probably exist. In particular aflatoxin, a mycotoxin
from the mould Aspergillus flavus, may be an important initiator in certain parts of
Africa, perhaps by acting as a cocarcinogen with Hepatitis B. It is certainly a potent
animal carcinogen and there is a close correlation between geographical HCC
incidence and calculated aflatoxin exposure distribution21. Membranous obstruc-
tion of the inferior vena cava is a well recognised problem in the Far East, India and
Southern Africa and it too has been suggested as being an aetiological factor for
HCC. In one series from South Africa 48% had associated HCC22. Smoking,
irradiation, cytotoxic therapy and sex hormone therapy may also have a role to play
in occasional tumours. In addition there are reports that chronic infections of the
23 24 liver such as schistosomiasis and clonorchiasis may be associated with HCC but
the evidence here seems less strong.
PATHOLOGY AND NATURAL HISTORY
It is often stated that small and encapsulated tumours are common in the East but
rare in the West25. When present encapsulation seems to be a favourable prognostic
sign
26-28 and this has been used by some to explain the better surgical results from
Japan. However, the evidence is misleading. Most Western series are of surgically
treated cases and depending on local referral practice a large number of patients
may have been excluded. In addition there is no universally accepted definition ofREGIONAL DIFFERENCES IN LIVER CANCER 123
encapsulation and its reported incidence varies widely not only between countries
but also between different centres in the same country. The Liver Cancer Study
Group of Japan
26 reported macroscopic evidence of encapsulation in 80% of cases
of HCC but Nakashima et al.
29 also from Japan, reported encapsulation in only
23% of their cases. Neither report defined how encapsulation was assessed.
Nagorney et al.
3 from the USA showed tumour encapsulation in 20% of 110 cases
and Kemeny et al. 31 in reporting 26 resected HCC’s in cirrhotic patients in the West
showed that histologically and morphologically they were similar to those encoun-
tered in the East. Small and encapsulated HCC is now being diagnosed and treated
in the West and will probably be increasingly reported as it is increasingly looked
for and as tumours are detected earlier.
Hepatocellular carcinoma is usually regarded as rapidly growing, but may not
always be so. There seems to be a wide range of growth rates with some tumours
growing rapidly and some slowly32. In some cases the disease may have been
present for 3 years or more before detection33. There have only been two large
studies where untreated small hepatocellular cancers were followed using ultra-
sound, one from Japan
34 and one from Taiwan33. Sheu et al. showed a mean
doubling time of 117 days with a range of 29-398 days and found that doubling time
was independent of the patient’s age, sex, HBsAg status, degree of cirrhosis and
histological type or grade. Nakashima et al. 29’35 showed that many small liver
cancers are found at autopsy in cases of advanced cirrhosis. These may be slow
growing or latent carcinomas which would never need surgery. The natural history
of untreated small liver cancer less than 3 cm has been reported as showing a
survival rate of 12.8% at three years after detection and any therapeutic modality
must thus be judged against this figure34. Similar studies on growth rates in
untreated cases are not available from the West and are unlikely ever to be
performed. Unfortunately this makes it difficult to directly compare the natural
history of Western and Eastern tumours. All that can be said is that there is
currently no convincing evidence that HCC’s from the East are fundamentally
different in their growth rates to those from the West.
Fibrolamellar carcinoma, a variant of HCC, also demonstrates marked regional
differences. Its distribution seems to be the reverse of the usual form and whilst it is
rare in the East35 it was found in 7% of one Western series36. A review of the
literature found 143 reported cases which included only 3 from Asia35 and the Liver
Cancer Studyd Group of Japan reported no cases in a survey of over 12,000 liver
cancers26. Why this remarkable geographical variation should be so is not clear. It
occurs in a younger age group and in non-cirrhotic livers and it is possible that
different, and as yet unidentified, carcinogenic factors may be involved.
SCREENING
As with many cancers it has been suggested that early diagnosis offers the best
chance of cure. Evidence for this proposal has now emerged from the reports of the
26 38 40 Liver Cancer Study Group of Japan They suggest that patients with chronic
liver disease, particularly cirrhosis, should be followed at regular intervals using
ultrasound(US) and measurement of alpha-fetoprotein.
Alpha-fetoprotein is a useful aid in the diagnosis of and screening for hepatocel-
lular carcinoma. Some authors have stated that Western patients with HCC are less124 T. EZAKI ET AL.
likely to have elevated AFP levels than those in the East41 but intercomparison of
such data is difficult. Raised AFP levels are commonly found in chronic hepatitis
and cirrhosis and there is no worldwide agreement on what levels should be
regarded as significant. In addition detection of tumours at an earlier stage will
result in fewer being AFP positive at the time of presentation42. Indeed the Liver
Cancer Study Group of Japan have found that the incidence of AFP positive
patients has decreased from 70% to 50% in successive surveys
26 and they attribute
this to the earlier detection of tumours due to screening.
Okuda has recommended that follow up with AFP and ultrasound should be
performed every 2-4 months depending on the degree of risk43. This policy, which
was first applied in the East, has enabled the detection of HCC’s at an early stage
when partial hepatectomy or limited resection is still possible18’19’22’6’38-4. The
success of these screening programs should encourage a similar approach in high
risk patients in the West.
SURGICAL TREATMENT
It is important to define indications and contraindications for resection of HCC in
patients with liver cirrhosis. Assuming the tumour is anatomically resectable then
the level of albumin, bilirubin, prothrombin time and the general nutritional state
of the patient are the most important factors. Using Child’s classification44, patients
in Child A and B are good surgical candidates. However, perioperative morbidity
and mortality also depends on the volume of the operative blood loss and the extent
of resection performed. In Japan the value of the indocyanine green (ICG)
retention test has been studied
45 as a possible indicator of functional liver cell mass.
ICG is removed from the circulation by the liver and its rate of removal therefore
reflects liver cell function46. The test is, however, time consuming and relatively
expensive and the results are sometimes difficult to interpret, especially in the over
weight patient. For these reasons it is not commonly used in the West. Perhaps
more research is needed into ways of assessing functional liver cell mass in cirrhotic
patients where resection is contemplated.
During the last decade, liver surgery has become both safer and more widely
practised throughout the world due to technical advances and improved anaesthe-
siology and perioperative care47. In the West there was much initial resistance to
the concept of resection in the cirrhotic liver due to problems with intra- and
postoperative bleeding and postoperative hepatic failure. In eastern countries,
however, a large number of patients with HCC were treated surgically even in the
1970’s and the Eastern experience of resection for HCC is vast compared with that
of the West. Balasegaram et al. 48 carried out 288 resections, of which 99 were for
HCC in Kuala Lumpur with a 14.1% of mortality rate in the HCC cases. They
stressed the importance of limited resection in the case of severe cirrhosis. Liver
resection for HCC is now increasing in western countries where liver .surgery has
largely been developed on the basis of secondary liver cancer
49 and a gradual
increase in the number ofHCC cases undergoing hepatectomy in the cirrhotic liver
has been reported in western Europe5. In the USA, Iwatsuki et al.
51 have reported
their enormous experience with 411 hepatic resections, in which they showed a
gradual increase of HCC resections with a mortality of 7.3%. Most of these were
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fatal cases were complicated by cirrhosis. They also pointed out that recurrence
dominated the actuarial survival rate after resection for primary malignancy, and
their survival figures were 68.5% and 31.9% at 1 and 5 years, respectively.
Follow-up studies after hepatectomy forHCC from some institutions have shown
remarkably high intrahepatic recurrence rates of 50% or more, particularly within
one to two years of operation52-54. This has led some authors to recommend more
radical surgery. It is difficult, however, to distinguish recurrence due to nonexcised
cancer tissue, unrecognized multifocal primary tumours or new primary tumours.
Chen et al. 55 examined five recurrent hepatocellular carcinomas in HBsAg positive
patients and found that in three cases the clonality of the second cancer differed.
Tumour thrombus of the portal vein freuently occurs with tumours 3-5 cm in
diameter
38 and resection with limited margins might result in tumour dispersal due
to manipulation56. Yoshida et al. 57 examined the surgical resection margin in
relation to recurrence of HCC following resection and suggested that a resection
margin of 10mm is inadequate to achieve curability when the tumour size exceeds 4
cm. The problem should be addressed by a prospective trial with intraoperative
ultrasonography to ensure second tumours are not left behind and to assess the size
of resection margins58. Only when such information is available may it be possible
to meaningfully study differences in recurrences rates between different centres.
Tumours which are unresectable due either to poor liver function or anatomical
reasons have been treated by liver transplantation if extra-hepatic spread has not
occurred. Liver transplantation has until now been performed largely in the USA
and Western Europe and has not been an option in the Fat East and Japan. The
published results of liver transplantation for HCC have, however, been
disappointing59-63. Iwatsuki et al.6 reported that two-thirds of the patients deve-
loped tumour recurrence and less than a quarter of the patients survived 3 years.
However, patients referred for transplantation are usually those whose tumour is
not suitable for conventional resection and this will immediately bias the results.
Also when transplantation has been carried out for end-stage cirrhosis with
incidental malignancy very much better results have been reported59’62. No
controlled trial of liver resection versus liver transplantation as a treatment for
HCC in the cirrhotic liver has been published and the question of which might be
the best treatment remains unanswered.
CONCLUSION
Hepatocellular carcinoma remains a largely untreated disease worldwide
64 and
unfortunately the countries with the highest incidence often have the poorest
resources to deal with it. There is currently no firm evidence to suggest that, except
for the fibrolamellar variant, the fundamental nature ofHCC differs between high-
risk and low-risk countries, although there is a difference in the nature of the
associated cirrhosis. The true role of the HBV, and possibly other hepatitis
viruses12 as initiators has not yet been fully determined and the future of this
exciting aspect of research lies with the molecular biologists. In areas whereHBV is
endemic an active childhood immunisation policy may be useful65’66 and several
such programs have already begun66.
The best hope of cure, at present, is surgical removal after detection of the
tumour at an early stage. In the future liver transplantation may play an increasing126 T. EZAKI ETAL.
role in developed countries, especially for a small tumour in a severely cirrhotic
liver. In Great Britain and Europe more patients should be referred for assessment
to specialist centres and patients with chronic liver disease should be considered for
regular screening. Finally, in order to learn more about this tumour and study what
differences there may be in its behaviour worldwide, we need carefully constructed
surveys and screening programs of which those in Taiwan and Japan are currently
the best examples.
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